Compare Garmin Ltd. (GRMN) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Eli Lilly And Co — how do they compare? Garmin Ltd. trades at $268.45 (market cap $51.77B), while Eli Lilly And Co trades at $1,163.51 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 20.1× Garmin Ltd.'s market cap, and Garmin Ltd. pays the higher dividend (1.56%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Eli Lilly And Co for 93 Days on average.
| GRMN | LLY | |
|---|---|---|
Market Cap | $51.77B | $1.04T |
Volume | 961,398 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $313.16 | $1.28K |
52-Week Low | $187.10 | $799.57 |
Typical Hold Time | 83 Days | 93 Days |
Enterprise Value | $49.28B | $1.09T |
Dividend Yield | 1.56% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $276.16, down 1.09% on the day, with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $4.9B in 2022 to $7.25B in 2025, and robust profitability margins. Recent news highlights product innovation and industry awards, reinforcing its market position.
The outlook is supported by solid financial health and analyst consensus pointing to upside, but risks include competitive pressures and market volatility. The stock presents a growth opportunity driven by execution, though investor caution is warranted near-term given technical weakness and macroeconomic uncertainties.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
